Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
And if they start nailing the 200...plus DCV...plus the USA gets involved...wow
I am not holding this for a flip. Not the reason I purchased in the first place. This is a legit company with outstanding prospects. I'm in for the long haul and a much higher price than .26 cents...
Anyone hear anything???
IMO I think we can do much better.
This is the ground floor. I trust Dr. Tate running the show. This story will continue to unfold, shareholders will be rewarded.
Uno healthcare agreement video...
The Company is also pursuing other approaches to increase its capital resources such as combination with revenue-generating private entities, out-licensing of its intellectual property, sale of assets or other transactions that may be appropriate.
Happy to see you posting. Always appreciate your insight.
Imagine what that would mean!!! Wow
Agreed
Would any one of those idiots want the pipeline running right thru their backyard or neighborhood? I think not. Maybe we should build a space colony on Mars instead of trying to solve our energy dependence. Big oil companies are putting dollars into algae, guess their stupid too...
I wonder what 1 single good PR would do for a company with such a low number of outstanding shares...
Obama Mocks Drilling For Oil – Pushes Green Algae Pond Scum Instead
Posted by Jim Hoft on Friday, February 24, 2012, 5:45 AM
It’s an Obama world.
Obama mocks drilling for oil – pushes green algae instead
Barack Obama admitted Thursday that he didn’t have any clear solutions to the surging gas prices. However, he did propose using algae to bring down the price.
The Examiner reported:
“We’re making new investments in the development of gasoline, diesel, and jet fuel that’s actually made from a plant-like substance, algae — you’ve got a bunch of algae out here,” Obama said at the University of Miami today. “If we can figure out how to make energy out of that, we’ll be doing alright. Believe it or not, we could replace up to 17 percent of the oil we import for transportation with this fuel that we can grow right here in America.”
February update:
If they do anything close to the numbers in the report plus all the other possibles, this will be a BIG winner!
I just don't think there is any news to tell. The economies for alternative fuels are dead. I'm sure if gas hits 5 we will see a big surge. With this low of a float who knows what a contract would do...
Agreed. It is nice to see some chatter again, let's hope they give us more reason soon.
Article from September of last year. More exposure...
Moms Receive EU Orphan Drug Designation From European Medicines Agency For Novel Cholesterol Drug Called Cyclodextrin
September 14, 2011 by Chris Hempel
Filed under Featured Stories
6 Comments
Last year, after Dr. Caroline Hastings and I received the U.S. Food and Drug Administration orphan drug designation for Hydroxy-propyl-beta-cyclodextrin (HPBCD) for the treatment of Niemann Pick Type C disease, I was contacted by Sue French.
Addi and Cassi's Intravenous Cyclodextrin Solution - HPBCD Is A Powerful Drug
Sue lives in the United Kingdom and her son William is also afflicted with the rare and fatal genetic cholesterol disease called Niemann Pick Type C disease like Addi and Cassi. The French family run the Niemann-Pick Research Foundation (NPRF) in the UK.
Sue and I discussed her interest in seeking compassionate use of Hydroxy-propyl-beta-cyclodextrin in the UK to treat patients like her son. She was keen to learn more about how we are treating Addi and Cassi with cyclodextrin in the U.S.
The problem facing Sue and other families throughout the European Union (EU) is that many doctors have never heard of cyclodextrin. They do not understand that some cyclodextrins (like HPBCD) have been discovered to be active pharmaceutical ingredients (APIs) and have massive effects when they interact with cholesterol in the human body.
While U.S. citizens look to the FDA for drug designations and approvals, in the European Union a different authority governs drugs. It’s called the European Medicines Agency or EMA.
Sue and I decided that in order to further legitimize cyclodextrin as a potentially lifesaving therapy throughout the EU for Niemann Pick Type C patients, we needed to work together to pursue an orphan drug designation from the EMA.
I discussed the concept with Dr. Hastings who was willing to support our efforts to move the EMA application forward in order to help open avenues of treatments for patients throughout the EU. We also talked about how we could potentially utilize the combined FDA and EMA Single Orphan Drug Designation Annual Report process that was announced by both agencies in February 2010.
Sue and I began the process of re-purposing the FDA filing to create the EMA application. Sue took the lead on establishing contact with the Orphan Drug Group at the EMA and started the first draft of the EMA application. We then had the application reviewed by Dr. Hastings and Dr. Ron Browne (a consultant we hired to help us with FDA protocol filings).
After submitting our initial draft, we held a conference call with the EMA where I had to give a presentation on cyclodextrin. Dr. Jordi Llinares, head of Orphan Medicines at the European Medicines Agency (EMA) was on the call and provided valuable feedback on how to make the submission even stronger.
After the call, Sue and I spent the next few months going back and forth on email refining the draft (in between caring for our kids!). We finally reached a point where we had all the data necessary data for the EMA orphan drug submission. After holding one final conference call with the EMA staff, Sue raced off to meet the deadline and submit all the documents and medical rational for cyclodextrin as a treatment for Niemann Pick Type C disease. Since we are not a pharmaceutical company, Sue acted as the “Sponsor” of the application because an EU citizen or company needs to officially apply.
In June 2011, we received a positive opinion from the Committee for Orphan Medicinal Products (COMP) for Hydroxy-propyl-beta-cyclodextrin for the treatment of Niemann Pick Type C. Seven other pharmaceutical companies seeking orphan drug designations for different products (including Novartis and Pfizer) were also listed along with us — not too shabby!
In August 2011, Dr. Hastings was the first to receive word from the EMA that our application for cyclodextrin was approved. I was so happy, I cried.
To give you an idea of how amazing this is, in 2010 a total of 174 orphan applications were submitted to the EMA and 128 received the designation. The 128 applications that received the designation are potential drugs to treat over 7,000 different rare diseases that affect over 30 million people in the EU. We have made it into an elite group with many leading pharma companies creating promising new therapies for rare diseases!
Sue and I are now back to working from our homes to move cyclodextrin clinical trials forward to prove it works in people. I work on this drug development effort right from the middle of my kitchen — no better place than the heart of your home!
Despite being on different continents, we are pushing forward cyclodextrin treatments for our children, and other NPC children like them, to give them a real chance at life.
This will explode! Musik is brilliant, all he needs is some help on the business side....BOOOOOM
Meet The Children Who Are Resistant To Contracting Ebola, HIV-AIDS
December 27, 2011 by Chris Hempel
Filed under Featured Stories
1 Comment
My life grows more surreal by the day.
Addi and Cassi's cells are resistant to deadly viruses like Ebola and HIV-AIDS
Four years ago, I was told that my eight year old identical twins have a fatal genetic cholesterol disease called Niemann Pick Type C (the “Childhood Alzheimer’s”) and they would likely not live to see their 10th birthday.
Now I have learned from top virus scientists that the same cholesterol gene that is trying to kill my twins – Niemann Pick Type C or NPC1 – appears to be the critical gene that allows a number deadly viruses like Ebola, Marburg and HIV-AIDS to infect humans.
Because my twins’ NPC cholesterol genes are non functional, scientists have learned their cells are resistant to contracting Ebola and HIV-AIDS (and probably a host of other viruses that use the NPC gene pathway to infect humans). Read the research announcement here. They actually want to “give” NPC disease for short period of time if someone gets Ebola — turn the gene off temporarily so the virus can’t replicate, then turn it back on.
You can understand more about the implications and importance of the NPC gene if you also read the Department of Defense Ebola and NPC announcement. What the DoD did in their experiment is take donated skin cells from NPC kids like Addi and Cassi and they tried to infect their cells with the Ebola virus. What they discovered is that the Ebola virus can’t enter into the cells taken from kids like mine but in healthy people’s cells the virus can enter, replicate and kill. It appears that the NPC1 gene on Chromosome 18 is some type of master controller for many viruses and NPC kids are seemingly protected from certain viruses due to their genetic cholesterol defect.
Years ago, a leading HIV-AIDS researcher discovered a similar effect with the NPC gene. His lab reported that the NPC1 gene (and cholesterol) are critical for the HIV-AIDS virus to infect the human cell and replicate. I have been told that Addi and Cassi are likely resistant/immune to HIV-AIDS and probably a whole host of viruses that utilize lipids rafts to do their dirty work in the human body.
The emerging Niemann Pick Type C gene and virus story reminds some people of the sickle cell anemia discovery. Doctors found that patients who had sickle cell anemia, a serious hereditary blood disease, were more likely to survive malaria, a mosquito-borne infectious disease that kills millions every year. They believe that sickle cell gene carriers have been “naturally selected” because the sickle cell carrier trait gives resistance to malaria.
I wonder what Vincent Racaniello, writer of the Virology Blog, or Ian Lipkin, “the famous Virus Hunter” would think of the Niemann Pick Type C story? Kids dying of an ultra rare genetic cholesterol disease resistant to deadly viruses? There must be some major clues here?
I find it interesting that virus researchers are not asking NPC parents like me what viruses NPC kids can contract. It seems like a logical question? For example, the twins contracted Rotavirus at three and they were both hospitalized as a result. Maybe Rotavirus uses a different pathway from NPC to infect people?
In 2006, the twins and our family were afflicted with a very mysterious and horrendous virus. The twins and I were sick for many months and I have reported on this widely when interviewed by the media. Since we live between Reno and Incline Village, I believed for close to two years that this virus was XMRV. I had my family tested (we were “positive”). I have since learned that XMRV was due to lab contamination and it looks like we were not positive at all ….. but I am still baffled by the virus we contracted in 2006.
Stanford immunologists were baffled as well — they told me it looked like EBV/Mono but they were not positive with the way it was acting over time. You could see increased titers in their blood (which Stanford still has kindly stored for me and it could be looked at today).
For the past three years, we have had FDA approval to treat the twins with cyclodextrin (HPbCD), a non-toxic sugar compound that also inactivates the HIV-AIDS virus. Why a single AIDS patients has not contacted me about HPbCD is absolutely mind-blowing since it could be used today as a treatment. If nothing else works, I don’t see why cyclodextrin can’t be tried.
HPbCD is similar to Methyl Beta Cyclodextrin (MBC), which was recently reported to kill RSV. The RSV virus discovery was also made with NPC cells — do you see the trend emerging with the NPC1 gene? A 2003 HSV paper shows cyclodextrin can work against Herpes Simplex Virus 1/2. There are many viruses that can be inactivated or cell-entry blocked by cyclodextrin. Basically, any virus that uses lipid rafts for assembly or entry can be blocked by beta cyclodextrin – and there are probably at least 20 virus types that would be inactivated by beta cyclodextrin. I also believe people with these viruses could be treated with HPbCD today – just like my twins.
It is quite clear that intravenous treatment with cyclodextrin has had a very positive effect on the twins’ immune system. But no one can tell me why. Whatever virus they had lingering is now gone, and for the past three years, the twins have not been sick. Of course, they still have Niemann Pick Type C disease but they have not contracted anything — no flu, no fever – nothing! It’s remarkable and the twins’ physician will confirm what I am saying about their immune system. Since they are identical twins and both responded the same way to cyclodextrin, we are quite sure there is a biological effect!
Just as with the sickle cell anemia story, I feel I am in the middle of an evolutionary detective story. I hope we can get to the final chapter quickly.
Still here and frustrated as can be. There needs to be an update or don't put out a freakin press release that says there is gonna be. I can't believe half baked companies like this can be allowed to operate. Shareholder interest? Do us all a favor and stay private...
Nice update. Looking forward to 2012.
That's what I was thinking...
"after this significant change
about his expectations of his capability to market products
produced with the Nanosonic facility."
Forgive me for not paying attention but what changed???
When were the expectations changed?? I missed it???
TIA
Strat is a no nonsense guy. I called him once a while back and he was straight and to the point. If you want to email you can email Tate if you want to talk pick up the phone and call Strat...
Complete agreement. This one is a keeper...
HOW LOW CAN IT GO??? ZERO...
I have a lot of this one already.
Buy more or catch a falling knife?
I'll change that...this is worse than watching paint dry.
Anxious to see what they have done so far and what they will do in the future. This will be a future big winner IMO...
Not by a long shot, which is what I think this is...
This is looking really good right now. Manufacturing has begun, bio conference, interesting products, hints of future expansion. I've been accumulating and will continue to do so.
I don't think the .50 cent mark is far away. Longer term I see much more imo
It feels like something is about to pop on this...
I hope so. Its been like watching paint dry.
What the hell is going on here? Talk talk talk...no action. This is beyond frustrating.
Could be. Do you any price targets in mind? Seems like with all the business available and regulations...skys the limit
100 million cap? Anyone want to go higher? I hope you are right...
What price targets do you all have on CTDH???